Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, October 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 16 X posts from 15 X users, with an upper bound of 51,495 followers.

@matthewherper @VPrasadMDMPH FWIW here’s a nice review. Process took about a year. Maybe should’ve gone with ODAC the first time? https://t.co/c3x3atvz5F https://t.co/2plcIHXT91

Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study https://t.co/vXhAbxtV48

On the challenges of withdrawing drugs given early/conditional approval - as mentioned by Prof Ralston #rcpeabdn17 https://t.co/dJpw11l431

Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study #ResearchRounds https://t.co/dmsooY0XJY

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.